John Hunter - COMPUGEN VP

<div class='circular--portrait' style='background:#82ADFD;color: #ffffff;font-size:4em;padding-top: 25px;;'>CO</div>
CGEN -- Israel Stock  

ILA 4,802  273.00  5.38%

  VP
Mr. John Hunter is Vice President Antibody Research and Development of Compugen Ltd. Dr. Hunter has worked for 18 years on different aspects of oncology drug development. Following graduation from UCSF, from 1996 to 2003, Dr. Hunter worked for Millennium Pharmaceuticals Inc., where he employed genomic approaches to identify novel drug targets in lung cancer. As a founding member of Millenniums Translational Medicine group he worked to develop clinical biomarkers for their Aurora kinase small molecule inhibitors. Following Dr. Hunter employment at Millennium, Dr. Hunter joined Xenogen Corporationration, where he worked as Senior Scientist in Oncology from 2004 to 2005. Dr. Hunter later joined XOMA Ltd., where from 2005 to 2012 he managed early stage antibody discovery for multiple therapeutic programs in oncology and inflammation. Dr. Hunter currently leads therapeutic antibody research and development efforts for Compugens portfolio of novel oncology targets.
Age: 52  VP Since 2012      
(972) 3 765 8555  www.cgen.com

John Hunter Latest Insider Activity

COMPUGEN Management Efficiency

COMPUGEN has return on total asset (ROA) of (0.5516) % which means that it has lost $0.5516 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (78.0668) % meaning that it generated substantial loss on money invested by shareholders. COMPUGEN management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. As of June 2, 2020, Return on Investment is expected to decline to -86.62. The current year Return on Average Assets is expected to grow to -0.0055COMPUGEN Total Assets are expected to significantly increase based on the last few years of reporting. The last year's Total Assets were at 53.76 Million. The current year Current Assets is expected to grow to about 91 M, whereas Return on Average Assets are expected to grow to (0.0055) . The current year Current Liabilities is expected to grow to about 6.9 M, whereas Total Liabilities is expected to decline to about 13.2 M.
The company has accumulated 3.31 M in total debt with debt to equity ratio (D/E) of 0.03 which may suggest the company is not taking enough advantage from borrowing. COMPUGEN has Current Ratio of 7.05 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Company Summary

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company was incorporated in 1993 and is headquartered in Holon, Israel. COMPUGEN operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 61 people.COMPUGEN (CGEN) is traded on Tel Aviv Stock Exchange in Israel and employs 61 people.

COMPUGEN Leadership Team

Joshua Shemer, Independent External Director
Michal Preminger, Director
Paul Sekhri, Chairman of the Board
Dov Hershberg, Director
Martin Gerstel, Chairman of the Board
Arie Ovadia, Independent External Director
Zurit Levine, Vice President - Research and Discovery
Eran Perry, Director
Ari Krashin, Chief Financial Officer
Sanford Zweifach, Director
Gilead Halevy, Director
Anat CohenDayag, President, Chief Executive Officer, Director
Ruth Arnon, Independent Director
Kinneret Savitsky, Director
Henry Adewoye, Chief Medical Officer
Yair Aharonowitz, Independent External Director
JeanPierre Bizzari, Director
John Hunter, VP of Antibody RandD and Site Head of Compugen USA Inc

Stock Performance Indicators

Did you try this?

Run Stock Tickers Now

   

Stock Tickers

Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
All  Next Launch Module

COMPUGEN Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for COMPUGEN and EVOGENE LTD. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
 2016 2017 2019 2020 (projected)
Receivables Turnover0.137808177.11159.4171.98
PPandE Turnover0.1184124.444.03.18
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company was incorporated in 1993 and is headquartered in Holon, Israel. COMPUGEN operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 61 people.
Continue to Trending Equities. Please also try Balance Of Power module to check stock momentum by analyzing balance of power indicator and other technical ratios.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page